EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Weizmannia coagulans SA9: A Novel Strategy to Alleviate Type 2 Diabetes

Linhao Wang iD, Jie Wang, Yewei Tan, Changyu Cai, Xiaohua Yang, Sashuang Dong iD, Jiaqi Hong, Xiang Fang iD, Hong Wei, Zhenlin Liao

Nutrients · 2025

DOI: 10.3390/nu17132081 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nutrients, 2025. Verfasst von Linhao Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: College of Food Science, South China Agricultural University, Guangzhou 510642, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Probiotics. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key R&D Program Projects in Guangdong, P.R. China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Probiotics have recently emerged as promising agents in the prevention and treatment of various human diseases. This study investigates the therapeutic potential of Weizmannia coagulans SA9 in the management of type 2 diabetes mellitus (T2DM).

Methods

The in vitro antidiabetic activity of W. coagulans SA9 was primarily assessed via its α-glucosidase inhibitory capacity, complemented by metabolomic profiling to identify putative bioactive metabolites. The antidiabetic efficacy was further evaluated in a db/db mouse model, focusing on glucose tolerance, inflammatory biomarkers, and gut microbiota composition.

Results

W. coagulans SA9 showed significant inhibitory effects on α-glucosidase and α-amylase, and DNJ and other active substances were detected in its culture supernatant. After 6 weeks of continuous administration, the fasting blood glucose level, glucose tolerance, and inflammation indexes of mice were significantly improved. Beneficial changes in the structure of the intestinal flora occurred after the probiotic intervention, as evidenced by a significant decrease in harmful bacteria (e.g., Aerococcus urinaeequi) and a significant enrichment of beneficial bacteria (e.g., Limosilactobacillus reuteri).

Conclusions

W. coagulans SA9 exerts robust antidiabetic effects and holds promise as a novel strategy for the prevention and management of T2DM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2ProbioticsAnimalsGastrointestinal MicrobiomeMiceBlood GlucoseMaleHypoglycemic AgentsMice, Inbred C57BLGlycoside Hydrolase InhibitorsDisease Models, Animalalpha-Amylases

Stichwörter der Autor:innen

1-deoxynojirimycinWeizmannia coagulansgut microbiotatype 2 diabetes

Substanzen

Blood GlucoseHypoglycemic AgentsGlycoside Hydrolase Inhibitorsalpha-Amylases

Autor:innen und Institutionen

  • College of Food Science, South China Agricultural University, Guangzhou 510642, China.
  • College of Animal Sciences and Technology, Huazhong Agricultural University, Wuhan 430070, China.

ORCID-Profile: Linhao Wang, Sashuang Dong, Xiang Fang

Förderung

  • Key R&D Program Projects in Guangdong, P.R. China

Zitieren

APA

Wang, L., Wang, J., Tan, Y., Cai, C., Yang, X., Dong, S., Hong, J., Fang, X., Wei, H., & Liao, Z. (2025). Weizmannia coagulans SA9: A Novel Strategy to Alleviate Type 2 Diabetes. Nutrients. https://doi.org/10.3390/nu17132081

Vancouver

Wang L, Wang J, Tan Y, Cai C, Yang X, Dong S, et al. Weizmannia coagulans SA9: A Novel Strategy to Alleviate Type 2 Diabetes. Nutrients. 2025. doi:10.3390/nu17132081

BibTeX
@article{Wang2025,
  author = {Wang, Linhao and Wang, Jie and Tan, Yewei and Cai, Changyu and Yang, Xiaohua and Dong, Sashuang and Hong, Jiaqi and Fang, Xiang and Wei, Hong and Liao, Zhenlin},
  title = {Weizmannia coagulans SA9: A Novel Strategy to Alleviate Type 2 Diabetes},
  journal = {Nutrients},
  year = {2025},
  doi = {10.3390/nu17132081}
}
Kostenlos starten →